AbbVie Inc.
AbbVie Reports 2024 Financial Results and Provides 2025 Outlook
Summary
AbbVie Inc. reported full-year 2024 diluted EPS of $2.39 on a GAAP basis, a decrease of 12.1%, and adjusted diluted EPS of $10.12, a decrease of 8.9%. Full-year net revenues increased by 3.7% to $56.334 billion. The company announced a GAAP net loss of $23 million for Q4 2024, driven by significant intangible asset impairment charges related to the Cerevel acquisition, and provided an adjusted diluted EPS guidance for 2025 of $12.12 to $12.32.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement